Creating
a new path

News & events

ASH 2016
Spark Phase 1/2 hemophilia B data selected from 6,600 abstracts to be featured in ASH 2016 scientific plenary

Read More read more

Pipeline updates
Learn more about Spark’s programs in hemophilia A and B

Read More read more

New resources
Explore some of the hemophilia-focused advocacy groups Spark works with

Read More read more

ID YOUR IRD
Genetic testing now available to eligible patients with certain IRDs through the new Spark initiative, ID YOUR IRD

Read More read more

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-mediated diseases such as hemophilia, and neurodegenerative diseases.

Learn More